Canine Leptospirosis Vaccine

Verify with FDA CVM →

109 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
109
Total Reports
9
Deaths Reported
830.0%
Death Rate

Active Ingredients

Canine Leptospirosis Vaccine

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Dog 109

Most Affected Breeds

Retriever - Labrador 20
Terrier - Bull - American Pit 7
Retriever - Golden 6
Boxer (German Boxer) 5
Bulldog - French 4
Chihuahua 4
Shih Tzu 4
Terrier - Jack Russell 4
Bulldog 3
Dog (other) 3

Most Reported Reactions

Vomiting 44
Lethargy (see also Central nervous system depression in 'Neurological') 21
Diarrhoea 15
Facial swelling (see also 'Skin') 12
Anaphylaxis 12
Fever 11
Seizure NOS 11
Lack of efficacy (endoparasite) - heartworm 9
Hives (see also 'Skin') 8
Pale mucous membrane 8
Anorexia 7
Not eating 7

Outcome Breakdown

Ongoing
60 (55.0%)
Recovered/Normal
26 (23.9%)
Outcome Unknown
14 (12.8%)
Died
5 (4.6%)
Euthanized
4 (3.7%)

Data Summary

Metric Value
Total adverse event reports 109
Reports involving death 9
Case-fatality rate (reported events) 830.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Leptospirosis Vaccine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 109 adverse event reports referencing Canine Leptospirosis Vaccine, including 9 reports in which the animal died — a 830.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Leptospirosis Vaccine. Reported administration routes include Unknown, Subcutaneous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Leptospirosis Vaccine reports are Dog (109 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (20), Terrier - Bull - American Pit (7), Retriever - Golden (6) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Leptospirosis Vaccine are Vomiting (44), Lethargy (see also Central nervous system depression in 'Neurological') (21), Diarrhoea (15), Facial swelling (see also 'Skin') (12). Of the 109 reports with a coded outcome, Ongoing is the leading category at 55.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Leptospirosis Vaccine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial